Baker Bros. Buys $35M of Madrigal Stock Days After First Profitable Quarter
MDGL is trading near its 52-week low of $353.54 (13% above the low) on elevated volume (3.1× avg).
Summary
Baker Bros. affiliates bought 91,806 Madrigal shares for $35.0M at $366.99-$396.61, lifting holdings to 2.04M shares — an open-market purchase days after the company's first profitable quarter.
Key Events · Ownership and Investor Activity · MDGL
-
Baker Bros. Buys 91,806 Shares
Baker Bros. Advisors LP and affiliated reporting persons acquired 91,806 shares for $35,023,032.10 in five open-market transactions on 2026-11-04 and 2026-11-06.
-
Purchase Prices $366.99-$396.61
Weighted-average fills ranged from $366.99 to $396.61 per share, with the largest single tranche 60,400 shares at $383.015.
-
Holdings Rise to 2.04M Shares
Post-transaction indirect holdings total 2,040,682 shares, held via 667, L.P. and Baker Brothers Life Sciences LP structures.
-
Follows First Profitable Quarter
The buying came days after the 2026-11-03 8-K/10-Q reporting $55.4M net income on $431.3M of Rezdiffra sales and $961.8M of cash.
Analysis · MDGL · Life Sciences
Why it matters: Baker Bros. Advisors and its affiliated funds, whose principals hold Madrigal board seats, bought 91,806 shares for $35.0M in the open market on November 4 and 6 — real cash, not option exercises. The timing is notable, coming days after Madrigal reported its first profitable quarter ($55.4M net income on $431.3M of Rezdiffra sales) and one-year data showing up to 93% of patients with improved or stabilized liver stiffness. A specialist biotech investor with board visibility adding at $367-$397 is a meaningful vote of confidence, though at roughly 0.4% of market cap it is a conviction signal rather than a thesis-changing event.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDGL was trading at $399.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $353.54 to $615.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.